150 related articles for article (PubMed ID: 27466552)
1. Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer.
Toyokawa G; Takada K; Haratake N; Takamori S; Akamine T; Katsura M; Fujishita T; Shoji F; Okamoto T; Oda Y; Maehara Y
Anticancer Res; 2016 Aug; 36(8):4329-36. PubMed ID: 27466552
[TBL] [Abstract][Full Text] [Related]
2. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
3. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T
J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of PD-L1 in bladder cancer.
Huang Y; Zhang SD; McCrudden C; Chan KW; Lin Y; Kwok HF
Oncol Rep; 2015 Jun; 33(6):3075-84. PubMed ID: 25963805
[TBL] [Abstract][Full Text] [Related]
6. An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
Takada K; Toyokawa G; Okamoto T; Akamine T; Takamori S; Katsura M; Fujishita T; Shoji F; Oda Y; Maehara Y
Anticancer Res; 2016 Jul; 36(7):3409-12. PubMed ID: 27354600
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM
Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847
[TBL] [Abstract][Full Text] [Related]
10. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
Sheng J; Fang W; Yu J; Chen N; Zhan J; Ma Y; Yang Y; Huang Y; Zhao H; Zhang L
Sci Rep; 2016 Jan; 6():20090. PubMed ID: 26822379
[TBL] [Abstract][Full Text] [Related]
11. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Igawa S; Sato Y; Ryuge S; Ichinoe M; Katono K; Hiyoshi Y; Otani S; Nagashio R; Nakashima H; Katagiri M; Sasaki J; Murakumo Y; Satoh Y; Masuda N
Oncology; 2017; 92(5):283-290. PubMed ID: 28222447
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
17. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
18. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
[TBL] [Abstract][Full Text] [Related]
19. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
